Superbugs and Superdrugs: a focus on antibacterials--6th annual SMi conference.
Georgopapadakou
Nafsika
N
Infectious Diseases, MethylGene, Montreal, PQ, Canada. nafsikag@aol.com
D000581:Amidohydrolases / Q000037:antagonists & inhibitors; D000818:Animals; D000900:Anti-Bacterial Agents / Q000145:classification / Q000494:pharmacology* / Q000627:therapeutic use; D001419:Bacteria / Q000187:drug effects*; D001424:Bacterial Infections / Q000188:drug therapy; D001426:Bacterial Proteins / Q000037:antagonists & inhibitors; D002511:Cephalosporins / Q000494:pharmacology; D002986:Clinical Trials as Topic; D017576:Daptomycin / Q000494:pharmacology; D015195:Drug Design; D004353:Drug Evaluation, Preclinical; D004351:Drug Resistance; D024901:Drug Resistance, Multiple, Bacterial; D006801:Humans; D048628:Ketolides / Q000494:pharmacology; D040541:Marketing; D051379:Mice; D011500:Protein Synthesis Inhibitors / Q000494:pharmacology; D012270:Ribosomes / Q000187:drug effects / Q000648:ultrastructure; D013329:Structure-Activity Relationship; D059005:Topoisomerase II Inhibitors; D065093:beta-Lactamase Inhibitors; D001618:beta-Lactamases / Q000502:physiology; D047090:beta-Lactams / Q000494:pharmacology
D000900:Anti-Bacterial Agents; D001426:Bacterial Proteins; D002511:Cephalosporins; D048628:Ketolides; D011500:Protein Synthesis Inhibitors; D059005:Topoisomerase II Inhibitors; D065093:beta-Lactamase Inhibitors; D047090:beta-Lactams; C443755:ceftobiprole; D000581:Amidohydrolases; C084507:peptide deformylase; D001618:beta-Lactamases; D017576:Daptomycin